Market Place
Sourcing Support
Bayer Unveils Positive Phase III Anticoagulant Data
23 Nov 2025 //
BUSINESSWIRE
Update On Phase 3 Librexia ACS Trial
15 Nov 2025 //
BUSINESSWIRE
Bristol Myers Squibb Presents Cardiovascular Portfolio Data
03 Nov 2025 //
BUSINESSWIRE
Milvexian Granted U.S. FDA Fast Track Designation for All Three Indications
25 May 2023 //
PRESS RELEASE
Milvexian Granted U.S. FDA Fast Track Designation in Phase 3 Librexia Program
25 May 2023 //
BUSINESSWIRE
BMS, J&J kick off pivotal studies of FXIa inhibitor milvexian
03 Mar 2023 //
PRESS RELEASE
The BMS-Janssen Collaboration Launches PIII Trial Evaluating Milvexian
02 Mar 2023 //
BUSINESSWIRE
Results From PII Study of Milvexian Show Favorable Antithrombotic Profile
28 Aug 2022 //
BUSINESSWIRE
New J&J CEO Duato points out 5 promising pipeline meds
11 Jan 2022 //
FIERCEPHARMA
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.